Information Provided By: 
Fly News Breaks for November 30, 2016
TXMD
Nov 30, 2016 | 08:35 EDT
Jefferies analyst Matthew Andrews attributes yesterday's slide in TherapeuticsMD to a short thesis presented by an investor at the Robin Hood Conference, though he views the thesis as a "hodgepodge" of topics, many of which have already been expressed by bears. Andrews said nothing in the short call impacts his expectation for positive REPLENISH trial data and sales of Yuvvexy and TX-001HR. He keeps a Buy rating and $18 price target on TherapeuticsMD shares.
News For TXMD From the Last 2 Days
There are no results for your query TXMD
